{"schema_version":"secwatch.filing_event.v1","accession":"0001654954-24-014204","form_type":"8-K","ticker":"CVM","cik":"0000725363","company_name":"CEL SCI CORP","filed_at":"2024-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:10.919352+00:00","generated_at":"2026-05-30T01:23:52.641504+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"CEL-SCI appoints Dr. Nabil Saba as lead for Phase III Multikine study in head and neck cancer","bullets":["Dr. Saba will serve as global Phase III confirmatory trial lead and Study Steering Committee member for Multikine.","He is a recognized head and neck cancer expert, professor at Emory, and has led over 50 clinical trials.","Appointment positions CEL-SCI for its upcoming confirmatory registration study in newly diagnosed head and neck cancer.","Dr. Saba chairs NCI head and neck cancer task forces and holds NIH funding for related research."],"urls":{"canonical":"https://secwatch.observer/filing/0001654954-24-014204","json":"https://secwatch.observer/filing/0001654954-24-014204.json","markdown":"https://secwatch.observer/filing/0001654954-24-014204.md","text":"https://secwatch.observer/filing/0001654954-24-014204.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/725363/000165495424014204/0001654954-24-014204-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/725363/000165495424014204/cvm_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T01:23:52.641504+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}